Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson PROCRIT / EPREX [reported separately through FY2021Q4] by Quarter
PROCRIT / EPREX (epoetin alfa) [reported separately through FY2021Q4] — International sales ($M) ($M)
Johnson & Johnson PROCRIT / EPREX [reported separately through FY2021Q4]: $58M in Q4 2021, down 12.1% from a year earlier. That is the lowest of the 21 quarters on record here. No newer figure appears in the documents we track.
Where the Q4 2021 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2022-02-17) ↗
Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | PROCRIT / EPREX (epoetin alfa) [reported separately through FY2021Q4] — International sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2021 | Jan 2, 2022 | 58 | -12.1% | Form 10-K (filed 2022-02-17) ↗ |
| Q3 2021 | Oct 3, 2021 | 65 | +3.2% | Form 10-Q (filed 2021-10-29) ↗ |
| Q2 2021 | Jul 4, 2021 | 69 | +4.5% | Form 10-Q (filed 2021-07-29) ↗ |
| Q1 2021 | Apr 4, 2021 | 64 | -19.0% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2020 | Jan 3, 2021 | 66 | +1.5% | Form 10-K (filed 2022-02-17) ↗ |
| Q3 2020 | Sep 27, 2020 | 63 | -12.5% | Form 10-Q (filed 2021-10-29) ↗ |
| Q2 2020 | Jun 28, 2020 | 66 | -5.7% | Form 10-Q (filed 2021-07-29) ↗ |
| Q1 2020 | Mar 29, 2020 | 79 | +1.3% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 29, 2019 | 65 | -7.1% | Form 10-K (filed 2022-02-17) ↗ |
| Q3 2019 | Sep 29, 2019 | 72 | -6.5% | Form 10-Q (filed 2020-10-23) ↗ |
| Q2 2019 | Jun 30, 2019 | 70 | -12.5% | Form 10-Q (filed 2020-07-24) ↗ |
| Q1 2019 | Mar 31, 2019 | 78 | -10.3% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 30, 2018 | 70 | +2.9% | Form 10-K (filed 2021-02-22) ↗ |
| Q3 2018 | Sep 30, 2018 | 77 | +10.0% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jul 1, 2018 | 80 | -1.2% | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2018 | Apr 1, 2018 | 87 | +11.5% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 68 | -6.8% | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2017 | Oct 1, 2017 | 70 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jul 2, 2017 | 81 | – | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2017 | Apr 2, 2017 | 78 | – | Form 10-Q (filed 2018-05-01) ↗ |
| Q4 2016 | Jan 1, 2017 | 73 | – | Form 8-K (a8k2017q4exhibit9915.htm, filed 2018-01-23) ↗ |
Breakdown
What makes up PROCRIT / EPREX [reported separately through FY2021Q4]
Cite this data
StockData. (2026). Johnson & Johnson PROCRIT / EPREX [reported separately through FY2021Q4] ($M), quarterly Q4 2016–Q4 2021 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-procrit-intl
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.